

American Nephrology Nurses Association

Daily Capitol Hill Update - Tuesday, September 1, 2020

The following information comes from directly from news sources including Bloomberg Government, Kaiser Health News, and other news sources.

Schedules: White House and Congress

WHITE HOUSE

- 10:30am: President Trump departs White House for Wis.
- 1:40pm: Trump visits damaged property in Kenosha, Wis.; tours emergency operations center at 2:15pm
- Trump participates in roundtable on community safety at 2:30pm
- Trump arrives back at White House at 6:15pm
- VP Mike Pence travels to Avoca, Pa.; speaks at “Workers for Trump” event in Exeter at 4:30pm

CONGRESS

- House, Senate out
- 1pm: House subcommittee on coronavirus holds hearing with Treasury Sec. Steven Mnuchin

Congressional, Health Policy, and Political News

- **The Hill: Mnuchin Says McConnell May Introduce New Coronavirus Bill Next Week:** Treasury Secretary Steven Mnuchin said Monday that Senate Majority Leader Mitch McConnell (R-Ky.) will “hopefully” unveil a new coronavirus relief bill next week. In an interview on Fox Business Network, Mnuchin was asked about the collapse of talks with Democrats over COVID-19 response and stimulus legislation. The secretary responded that he and White House chief of staff Mark Meadows have been regularly speaking with McConnell. “Hopefully Mitch will enter new legislation next week,” Mnuchin said.
- **The Hill: Lawmakers Call For Bipartisan Push To Support Scientific Research:** Lawmakers in both parties urged their colleagues Monday to invest in and work to develop a new, diverse generation of American scientists and researchers to help close the innovation gap with foreign rivals. In discussions held during The Hill’s “Science & American Advancement” event Monday, Democratic and Republican members of the House voiced support for boosting research funding and increasing the public interest in developing crucial technologies.
- **Stat: Mylan Launches Low-Cost Biosimilar Insulin, But Many Patients May Not Save:** Amid a national outcry over the cost of insulin, one of the largest generic companies launched a biosimilar version at a wholesale price it claimed is 65% less than comparable treatments, although experts say the move is more likely to benefit payers than many patients. Mylan (MYL) is marketing a long-acting version of the best-selling Lantus insulin

– which the company named Semglee – for adults with Type 2 diabetes, and adults and children with Type 1 diabetes. But Mylan maintained the price for a package of 5 pens is equivalent to what Lantus sold for in 2007, and that a 10 ml vial is listed at the same price for which Lantus was sold a decade ago.

- **Facebook Says It Can Block Content to Avoid Regulatory Risk:** Facebook today told users it can take down or block any content that could increase regulatory or legal risks for the social media giant around the world -- even if the content itself isn't illegal. The broad language of a global change to its terms of service, which takes effect Oct. 1, gives the U.S. giant room to do whatever it deems necessary to maintain its business objectives in a shifting regulatory environment.